This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Aerosolized Antibiotics and Respiratory Tract Infection in Patients on Mechanical Ventilation

This study has been completed.
Nektar Therapeutics
Information provided by:
Stony Brook University Identifier:
First received: November 6, 2006
Last updated: NA
Last verified: November 2006
History: No changes posted
The purpose of this study was to determine the effect of aerosolized antibiotics on respiratory infection in mechanically ventilated patients.We hypothesize that aerosolized antibiotics , which achieve high drug concentrations in the airway, would more effectively treat respiratory infection, decrease the need for systemic antibiotics and decrease antibiotic resistance.

Condition Intervention Phase
Ventilator Associated Pneumonia Respiratory Infection Tracheobronchitis Drug: aerosolized vancomycin or gentamicin Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Aerosolized Antibiotics in Mechanically Ventilated Patients

Resource links provided by NLM:

Further study details as provided by Stony Brook University:

Primary Outcome Measures:
  • Ventilator associated pneumonia Systemic Antibiotic use Clinical pulmonary infection score

Secondary Outcome Measures:
  • Weaning from mechanical ventilation Bacterial resistance

Estimated Enrollment: 80
Study Start Date: August 2003
Estimated Study Completion Date: September 2004
Detailed Description:
In patients requiring mechanical ventilation, signs of respiratory infection often persist despite treatment with powerful antibiotics given through the patient's vein. In this trial, patients with purulent secretions were assigned aerosolized antibiotics or placebo by a randomizing protocol. Neither the patients or their doctors knew what the patient was receiving.Need for a systemic antibiotic was determined by the clinical physician. Comparisons were made between placebo and study drug for their effects on pneumonia, respiratory signs of infection, ability to wean patients from the ventilator, systemic(given in the vein) antibiotic use and the development of organisms that were resistant to antibiotics.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • be on mechanical ventilation greater than 3 days
  • greater than or equal to 18 years of age survival greater than 14 days
  • greater than 2 ccs of tracheal secretions/4 hours

Exclusion Criteria:

  • allergy to drugs, pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00396578

United States, New York
University Hospital Medical Center
Stony Brook, New York, United States, 11794
Sponsors and Collaborators
Stony Brook University
Nektar Therapeutics
Principal Investigator: Lucy B Palmer, MD SUNY at Stony Brook
  More Information Identifier: NCT00396578     History of Changes
Other Study ID Numbers: CORIHS # 2004-3799
Study First Received: November 6, 2006
Last Updated: November 6, 2006

Keywords provided by Stony Brook University:
aerosolized antibiotics
ventilator associated pneumonia
clinical pulmonary infection score
bacterial resistance

Additional relevant MeSH terms:
Communicable Diseases
Respiratory Tract Infections
Pneumonia, Ventilator-Associated
Lung Diseases
Respiratory Tract Diseases
Cross Infection
Ventilator-Induced Lung Injury
Lung Injury
Anti-Bacterial Agents
Antibiotics, Antitubercular
Anti-Infective Agents
Antitubercular Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on September 21, 2017